Launching the agency’s plan for the next five years, Michael Lohan said the “vast majority” of the pharma products that leave Ireland for the US are intermediary, and face further processing there.
While he would not comment on whether that meant the pharma exports could avoid the tariffs that President Trump is threatening, Mr Lohan said there is a question about what point in the supply chain the levies are applied.
“If you have an unfinished product, it needs to be finished and completed before it is turned into revenue, and sale,” he said. “So the point at which the tariff is applied – is it the point of sale, or the point of transfer as it goes through a supply…